LLY Stock Recent News
LLY LATEST HEADLINES
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug Kisunla, saying the risk of serious brain swelling did not outweigh the treatment's small impact on slowing cognitive decline.
When looking for investment inspiration, it's a great idea to consider what some of the world's most successful investors are doing. Each one of their moves may not be right for your particular investment strategy, but you may find certain ones that offer just what you're looking for.
VIG's Index rebalanced last week and now counts Eli Lilly as its #5 holding with a 3.45% allocation. The ETF is on an impressive 11-year dividend growth streak. The Index yield dropped 0.04% to 1.81%, but VIG's components have five-year historical dividend growth rates and one-year estimated earnings growth rates around 10%. The dividend growth streak should continue. As a cross between a large-cap value and large-cap blend fund, VIG seems somewhat expensive, with a 20.49x forward P/E. I find it's somewhat complementary to SPY, with 43% overlap.
Over the last couple of years, the pharmaceutical sector has captivated investors thanks in large part to novel medications used to treat chronic weight management and diabetes.
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose and care for patients with Alzheimer's disease, potentially boosting sales of its drug Kisunla.
Currently, just eight vaunted stocks boast market capitalizations of over $1 trillion. This includes six of the Magnificent Seven stocks, as well as Warren Buffett's Berkshire Hathaway NYSE: BRK.A.
Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.